REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of options
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of options
Gaithersburg, Maryland - 10 September 2020: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that 1,150,000 options of common stock in the Company ("Options") were granted to Amanda Murphy on 8 September 2020, as part of a pre-agreed arrangement upon Amanda's appointment as the Company's new Chief Finacial Officer.
The Options vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 8 September 2020 (being the date of Amanda's appointment), of 330 pence.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Amanda Murphy
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
MaxCyte, Inc.
b)
LEI
54930053YHXULRFCU991
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Grant of Options over Shares of Common Stock
b)
Identification Code
US57777K1060
c)
Nature of the transaction
Grant of options
d)
Price(s) and volume(s)
1,150,000 options at an exercise price of 330 pence per common stock
e)
Aggregated information
- Aggregated volume
- Price
N/A
N/A
N/A
f)
Date of the transaction
8 September 2020
g)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
+1 301 944 1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith
+44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
Sukaina Virji
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHLMMTTMTIBBMM
